Patents Assigned to Katholieke Universiteit Leuven, K.U. Leuven R&D
  • Publication number: 20220203325
    Abstract: A miniaturized, automated method for controlled printing of large arrays of nano- to femtoliter droplets by actively transporting mother droplets over hydrophilic-in-hydrophobic (“HIH”) micropatches. The technology uses single or double-plate devices where mother droplets can be actuated and HIH micropatches on one or both plates of the device where the droplets are printed. Due to the selective wettability of the hydrophilic micropatches in a hydrophobic matrix, large nano- to femtoliter droplet arrays are created when mother droplets are transported over the arrays. The parent droplets are moved by various droplet actuation principles. Also, a method using two plates placed one top another while being separated by a spacer. One plate is dedicated to confirming and guiding parent droplets by using hydrophilic patches in a hydrophobic matrix, while the other plate contains HIH arrays for printing of the droplets.
    Type: Application
    Filed: March 21, 2022
    Publication date: June 30, 2022
    Applicant: Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Jeroen Lammertyn, Daan Witters
  • Publication number: 20220092869
    Abstract: A system for generating a mask for object instances in an image is provided. The system includes a first module comprising a trained neural network and configured to input the image to the neural network, wherein the neural network is configured to generate: pixel offset vectors for the pixels of the object instance configured to point towards a unique center of an object instance, the pixel offset vectors thereby forming a cluster with a cluster distribution, and for each object instance an estimate of said cluster distribution defining a margin for determining which pixels belong to the object instance. A method for training a neural network map to be used for generating a mask for object instances in an image is also provided.
    Type: Application
    Filed: January 17, 2019
    Publication date: March 24, 2022
    Applicants: Toyota Motor Europe, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Wim ABBELOOS, Davy NEVEN, Bert DE BRABANDERE, Marc PROESMANS, Luc VAN GOOL
  • Patent number: 11278859
    Abstract: A miniaturized, automated method for controlled printing of large arrays of nano- to femtoliter droplets by actively transporting mother droplets over hydrophilic-in-hydrophobic (“HIH”) micropatches. The technology uses single or double-plate devices where mother droplets can be actuated and HIH micropatches on one or both plates of the device where the droplets are printed. Due to the selective wettability of the hydrophilic micropatches in a hydrophobic matrix, large nano- to femtoliter droplet arrays are created when mother droplets are transported over the arrays. The parent droplets are moved by various droplet actuation principles. Also, a method using two plates placed one top another while being separated by a spacer. One plate is dedicated to confirming and guiding parent droplets by using hydrophilic patches in a hydrophobic matrix, while the other plate contains HIH arrays for printing of the droplets.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: March 22, 2022
    Assignee: Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Jeroen Lammertyn, Daan Witters
  • Patent number: 11186807
    Abstract: The present invention relates to the field of fermentation, more particularly to ethanol production. Even more particularly the present invention relates to reduced aroma production during fermentation processes. The present invention provides mutant alleles and chimeric genes useful to develop yeast strains to limit acetate ester levels during fermentation. In addition, the invention also relates to the use of such yeast strains as well as of compounds for the production of fermented foods and liquids with reduced acetate ester levels.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 30, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Kevin Verstrepen, Jan Steensels
  • Patent number: 11121422
    Abstract: Ionic compounds containing an anion, and a cation having the following structural formula (1): R1R2R3N+-(linker1)-O-(linker2)-(FC)??(1) wherein: R1 and R2 either linear or branched alkyl groups or together form a N-heterocylic ring with the nitrogen atom to which they are joined; R3 is linear or branched alkyl group; linker1 and linker2 are alkylene chains or polyether chains; and the group FC is a fluorinated alkyl group, as well as an electrolyte material comprising such an ionic compound and a metal salt, and metal-air batteries using such an electrolyte material. The invention also relates to a metal-air battery containing an electrolyte material, wherein the electrolyte material comprises at least one ionic compound and a metal salt, and wherein at least one ionic compound contains an anion CnF2n+1COO? or CnF2n+1SO3?, where in each case n is at least 1 and at most 10.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: September 14, 2021
    Assignees: TOYOTA MOTOR EUROPE, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Fanny Barde, Gijs Vanhoutte, Sandra Dorota Hojniak-Thyssen, Koen Binnemans, Jan Fransaer
  • Publication number: 20210087554
    Abstract: The present application relates to the field of inflammatory diseases, particularly to inflammatory diseases characterized by an M1 macrophage response, even more particularly to sepsis and to Trypanosoma infection. The invention provides substances modulating miR210 expression and/or activity, in particular RNA molecules inhibiting miR210 expression and/or activity and medical uses of these miR210 inhibitors. Methods are disclosed to screen for medicaments for treating sepsis.
    Type: Application
    Filed: October 3, 2017
    Publication date: March 25, 2021
    Applicants: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Massimiliano MAZZONE, Anne-Theres HENZE
  • Publication number: 20210077563
    Abstract: The present invention relates to non-naturally occurring anti-bacterial peptides. More specifically the peptides can be used to treat multi-drug resistant bacterial infections. In addition, the present invention provides methods for producing anti-bacterial peptides.
    Type: Application
    Filed: May 9, 2018
    Publication date: March 18, 2021
    Applicants: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Joost Schymkowitz, Frederic Rousseau
  • Patent number: 10881746
    Abstract: The present application relates to the field of neurological diseases, particularly to dystonia, even more particularly to primary dystonia, most particularly DYT1 primary dystonia. It is disclosed that the DYT1 dystonia causative mutation in TORSIN1A leads to hyperactivation of LIPIN. The invention provides substances modulating LIPIN function, in particular RNA molecules inhibiting LIPIN function and medical uses of these LIPIN inhibitors. Methods are disclosed to screen for medicaments that counteract the effects of TORSIN1A mutation.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: January 5, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R & D
    Inventors: Rose Goodchild, Micheline Grillet
  • Patent number: 10829528
    Abstract: The present invention relates to the field of disorders of the central nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that soluble amyloid precursor protein a (sAPP?) presents a particular binding site, which allows for binding to the GABABR1a receptor, thereby causing an agonistic effect through specific binding to Sushi domain 1 of GABABR1a. As a result, the frequencies of excitatory and inhibitory postsynaptic currents are reduced. Accordingly, the invention provides compounds able to interfere with the association of sAPP? with Sushi domain 1 of GABABR1a and as such with selective impairment of GABABR1sa beneficial in neurological and psychiatric disorders. The invention as well provides methods and (high content) screening assays for the production of said compounds.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: November 10, 2020
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Joris De Wit, Heather Rice, Bart De Strooper
  • Patent number: 10767182
    Abstract: The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: September 8, 2020
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D, Agency for Science, Technology and Research
    Inventors: Jean-Christophe Marine, Ernesto Guccione, Marco Bezzi
  • Patent number: 10695737
    Abstract: A novel miniaturized and highly automated method for the controlled printing of large arrays of nano- to femtoliter droplets is presented by actively transporting mother droplets over hydrophilic-in-hydrophobic micropatches. The proposed technology consists of single plate or double-plate devices where mother droplets can be actuated and hydrophilic-in-hydrophobic micropatches on one or both plates of the device where nano- to femtoliter droplets are printed. Due to the selective wettability of the more wettable hydrophilic micropatches in a hydrophobic matrix, large nano- to femtoliter droplet arrays are created when mother droplets are transported over these arrays. The parent droplets can be moved by different droplet actuation principles, for example, by using the principle of electrowetting-on-dielectric droplet actuation. We propose another method that uses two plates that are placed on top of each other while being separated by a spacer.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: June 30, 2020
    Assignee: Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Jeroen Lammertyn, Daan Witters
  • Patent number: 10633378
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: April 28, 2020
    Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Mohamed Koukni, Arnaud Marchand, Johan Neyts, Wim Smets
  • Patent number: 10612049
    Abstract: The present invention relates to genes conferring acetic acid tolerance in yeast. More specifically, the invention relates to the use of DOT5, preferably in combination with CUP2 and/or HAA1 to obtain acid tolerance in yeast. Even more preferably, the invention relates to specific alleles of said genes, and to yeast strains comprising said specific alleles.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: April 7, 2020
    Assignees: VIB vzw, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Johan Thevelein, Jean-Paul Meijnen, Maria Remedios Foulquié Moreno
  • Patent number: 10550123
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: February 4, 2020
    Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
  • Patent number: 10540536
    Abstract: Imaging mass spectrometry (IMS) has become a prime tool for studying the distribution of biomolecules in tissue. Although IMS data sets can become very large, computational methods have made it practically feasible to search these experiments for relevant findings. However, these methods lack access to an important source of information that many human interpretations rely upon: anatomical insight. In this work, this need is addressed by (1) integrating a curated anatomical data source with an empirically acquired IMS data source, establishing an algorithm-accessible link between them; and (2) demonstrating the potential of such an IMS-anatomical atlas link by applying it toward automated anatomical interpretation of ion distributions in tissue.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: January 21, 2020
    Assignees: Katholieke Universiteit Leuven, K.U.Leuven R&D, Vanderbilt University
    Inventors: Richard M. Caprioli, Bart De Moor, Raf Van De Plas, Nico Verbeeck, Etienne Waelkens
  • Publication number: 20190337954
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Application
    Filed: July 18, 2019
    Publication date: November 7, 2019
    Applicant: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
  • Patent number: 10450320
    Abstract: A series of 1,2,6,7,9,9a-hexahydropyrazino[1,2-d][1,2,4]triazin-4-one derivatives, substituted in the 8-position by an optionally substituted fused bicyclic heteroaromatic group, and in the 3-position by a range of functional groups, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: October 22, 2019
    Assignees: UCB Biopharma SPRL, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Helen Tracey Horsley, Richard John Mears, Judi Charlotte Neuss, James Thomas Reuberson
  • Patent number: RE48622
    Abstract: A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: July 6, 2021
    Assignees: UCB Biopharma SRL, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Daniel James Ford, Richard Jeremy Franklin, Anant Ramrao Ghawalkar, Helen Tracey Horsley, Qiuya Huang, James Thomas Reuberson, Bart Vanderhoydonck
  • Patent number: RE48801
    Abstract: This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: November 2, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D, Universiteit Gent
    Inventors: Jean-Christophe Marine, Eleonora Leucci, Joke Vandesompele, Pieter Mestdagh
  • Patent number: RE48856
    Abstract: The application relates to the field of cancer, particularly to the field of solid tumors. It was found that a particular long non-coding RNA (lncRNA), NEAT1, an essential architectural component of nuclear paraspeckles, is required for the survival of cancer, but not that of normal, non-transformed, cells. Inhibition of NEAT1 reduces cell viability of cancer cells and induces apoptosis. These data identify NEAT1 as a novel therapeutic target for treatment of solid tumors.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: December 21, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Jean-Christophe Marine, Laura Standaert